Table 1.
Clinical characteristics of eligible patients with recurrent ependymoma
| Patient characteristics | |
| Median age at enrollment (range) | 10 years (2–21 years) |
| Male | 14 (63.6 %) |
| Female | 8 (36.4 %) |
| Histology | |
| Ependymoma | 9 (40.9 %) |
| Anaplastic ependymoma | 13 (59.1 %) |
| Location of primary ependymoma | |
| Supratentorial | 11 (50 %) |
| Infratentorial | 11 (50 %) |
| Location of recurrence | |
| Locala | 19 (86 %) |
| Distant (outside of radiation field) | 3 (13 %) |
| Prior therapy | |
| Chemotherapy | 18 (82 %) |
| One systemic therapy | 13 |
| Two systemic therapies | 3 |
| Three systemic therapies | 2 |
| Radiotherapy | 22 (100 %) |
| Surgery | 22 (100 %) |
| Courses of lapatinib and bevacizumab | |
| Median (range) | 2 (1–14) |
| Response | |
| Objective responses (CR + PR) | 0 |
| n cases stable disease for >4 months | 4 |
| n cases progressive disease | 16 |
| Median time to progression | 7.9 weeks |
a
Four patients had evidence of metastatic disease upon enrollment as baseline disease evaluation and the disease was within the prior radiation field.